Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Fate Therapeutics (FATE) over the last 14 years, with Q3 2025 value amounting to -$627000.0.

  • Fate Therapeutics' Net Cash Flow rose 8415.87% to -$627000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 82346.67%. This contributed to the annual value of -$10.8 million for FY2024, which is 4483.68% up from last year.
  • Fate Therapeutics' Net Cash Flow amounted to -$627000.0 in Q3 2025, which was up 8415.87% from -$3.7 million recorded in Q2 2025.
  • In the past 5 years, Fate Therapeutics' Net Cash Flow registered a high of $79.5 million during Q1 2024, and its lowest value of -$84.4 million during Q2 2024.
  • Moreover, its 5-year median value for Net Cash Flow was -$3.7 million (2025), whereas its average is -$6.9 million.
  • As far as peak fluctuations go, Fate Therapeutics' Net Cash Flow tumbled by 410814.92% in 2021, and later skyrocketed by 51139.13% in 2024.
  • Quarter analysis of 5 years shows Fate Therapeutics' Net Cash Flow stood at $4.4 million in 2021, then plummeted by 571.5% to -$20.8 million in 2022, then surged by 141.12% to $8.5 million in 2023, then plummeted by 121.71% to -$1.9 million in 2024, then skyrocketed by 66.16% to -$627000.0 in 2025.
  • Its last three reported values are -$627000.0 in Q3 2025, -$3.7 million for Q2 2025, and $8.9 million during Q1 2025.